» Articles » PMID: 21099364

Transcriptional and Post-transcriptional Mechanisms of BAFF-receptor Dysregulation in Human B Lineage Malignancies

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2010 Nov 25
PMID 21099364
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Together, circulating BAFF and dominant receptor BAFF-R homeostatically regulate the humoral immune system. Consistently aberrant BAFF-R expression in leukemic cells reveals an intimate connection of these cells' malignant physiology to the BAFF/BAFF-R axis and also provides an additional survival mechanism to the expressing cells. In this study, we used primary cells and cell lines to interrogate the mechanisms underlying aberrant BAFF-R expression in precursor B acute lymphoblastic leukemia (precursor B-ALL) and mature B chronic lymphocytic leukemia (CLL). Here we demonstrate the aberrant expression of BAFF-R in precursor B-ALL cell lines and reveal that these cells acquire BAFF-R expression through premature transcriptional activation of the BAFF-R promoter in coordination with regulatory transcription factor c-Rel. Investigations using primary CLL cells provide a crucial counterpoint through their paucity of BAFF-R relative to their benign mature B cell counterparts, which we establish as functionally significant in its depletion of the CLL cells' BAFF-binding capacity. Furthermore, BAFF-R downregulation in CLL patients is revealed here to be restricted to the malignant compartment and mediated post-transcriptionally in order to compensate for the consistently unchanged levels of transcription factor c-Rel and BAFF-R mRNA. Finally, we present evidence that CLL cells retain endogenous mechanisms of BAFF-R regulatory control despite active receptor dysregulation.

Citing Articles

Targeting chronic lymphocytic leukemia with B-cell activating factor receptor CAR T cells.

Qie Y, Gadd M, Shao Q, To T, Liu A, Li S MedComm (2020). 2024; 5(9):e716.

PMID: 39224539 PMC: 11366826. DOI: 10.1002/mco2.716.


Receptor Activator of NF-κB (RANK) Confers Resistance to Chemotherapy in AML and Associates with Dismal Disease Course.

Clar K, Weber L, Schmied B, Heitmann J, Marconato M, Tandler C Cancers (Basel). 2021; 13(23).

PMID: 34885231 PMC: 8657109. DOI: 10.3390/cancers13236122.


TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss.

Li G, Zhang Q, Liu Z, Shen H, Zhu Y, Zhou Z Cancer Cell Int. 2021; 21(1):223.

PMID: 33865370 PMC: 8052726. DOI: 10.1186/s12935-021-01923-x.


BAFF/APRIL System Is Functional in B-Cell Acute Lymphoblastic Leukemia in a Disease Subtype Manner.

Sevdali E, Katsantoni E, Smulski C, Moschovi M, Palassopoulou M, Kolokotsa E Front Oncol. 2019; 9:594.

PMID: 31380267 PMC: 6657364. DOI: 10.3389/fonc.2019.00594.


Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.

Vicioso Y, Gram H, Beck R, Asthana A, Zhang K, Wong D Cancer Immunol Res. 2019; 7(7):1106-1119.

PMID: 31138521 PMC: 6606383. DOI: 10.1158/2326-6066.CIR-19-0058.


References
1.
Lin W, Gong Q, Seshasayee D, Lin Z, Ou Q, Ye S . Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood. 2007; 110(12):3959-67. DOI: 10.1182/blood-2007-04-088088. View

2.
Damle R, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-7. View

3.
Briones J, Timmerman J, Hilbert D, Levy R . BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol. 2002; 30(2):135-41. DOI: 10.1016/s0301-472x(01)00774-3. View

4.
Endo T, Nishio M, Enzler T, Cottam H, Fukuda T, James D . BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood. 2006; 109(2):703-10. PMC: 1890820. DOI: 10.1182/blood-2006-06-027755. View

5.
Molica S, Digiesi G, Mauro F, Mirabelli R, Cutrona G, Vitelli G . Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia. Leuk Res. 2008; 33(1):162-5. DOI: 10.1016/j.leukres.2008.05.004. View